

depression was performed with a single item of the Clinical Global Impression scale (bipolar version) (3). Because about one-third of the study participants had a mixed affective episode at inclusion and because improvement in depression was an outcome measure, use of a more quantifiable scale to quantify depression, e.g., the Hamilton Depression Rating Scale, could have made efficacy analysis balanced and more meaningful.

Another issue of concern is assessment variations. Although the authors attempted to control the effect of inter-centric assessment variations by loading study centers as a covariate in analysis of covariance, which we consider an indirect way of addressing interrater reliability, they failed to address the details of intracentric assessment. Considering that this is a multicentric study, such a description of intracentric assessment variations, if any, is important for interpretation of the results. In this study (1), use of analysis of covariance to control the effect of baseline psychopathology is not adequately justified (1), as there was no mention that baseline psychopathological scores differed significantly between groups. A further issue, under the safety analysis section, the authors could have provided the details (mean dose and pattern) of anticholinergic medication use.

The high attrition rate observed in both groups (79% in the placebo group and 58% in the aripiprazole group) was the main limitation of this study and hinted that the study findings were only preliminary evidence of aripiprazole's anti-manic property. Thus, further studies are needed to arrive at a robust conclusion regarding the benefits of aripiprazole in acute bipolar—mania and mixed—episodes.

References

1. Keck PE Jr, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G (Aripiprazole Study Group): A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. *Am J Psychiatry* 2003; 160:1651–1658
2. Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity and sensitivity. *Br J Psychiatry* 1978; 133:429–435
3. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W: Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. *Psychiatry Res* 1997; 73:159–171

KARUPPIAH JAGADHEESAN, M.B.B.S., M.D.
DAVID MUIRHEAD, M.B.B.S., F.R.A.N.Z.C.P.
Broadmeadows, Victoria, Australia

Typical Versus Atypical Antipsychotics

TO THE EDITOR: Stefan Leucht, M.D., et al. (1) concluded their meta-analysis by comparing the difference in relapse rates between atypical and typical antipsychotic agents to that produced by aspirin in preventing vascular events. But this comparison does not support the widespread use of atypical antipsychotics. A year's supply of enteric-coated aspirin costs less than \$10 and reduces the risk of fatal or disabling myocardial infarction and stroke by 8% per year. A year's supply of an atypical agent costs thousands of dollars more than a typical agent, but when compared to a typical agent, it reduces the risk of psychotic relapse by 8% per year.

This is not to diminish the impact of psychosis nor does it serve as an argument for reducing expenditures for those with

serious mental illness. Rather, it questions whether the billions of dollars currently spent on atypical antipsychotics might not produce a greater reduction in mortality, morbidity, and misery if spent on more robust interventions, such as assertive community treatment or supported employment and adequate housing. Perhaps providing atypical antipsychotic medication to a population that is 85% unemployed, has 10–20 times higher rates of homelessness, 8–10 times higher rates of criminal justice involvement, and 2–3 times higher rates of substance abuse is more like “giving an aspirin” than the authors had intended.

Reference

1. Leucht S, Barnes TRE, Kissling W, Engel RR, Correll C, Kane JM: Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. *Am J Psychiatry* 2003; 160:1209–1222

DANIEL LUCHINS, M.D.
Chicago, Ill.

The Nature of Traumatic Memories

TO THE EDITOR: Ruth A. Lanius, M.D., Ph.D., et al. (1) claimed that the differences they found in brain connectivity between subjects with posttraumatic stress disorder (PTSD) and comparison subjects “may account for the nonverbal nature of traumatic memory recall of PTSD subjects, compared to a more verbal pattern of traumatic memory recall in comparison subjects” (p. 36). This statement would seem to imply that there could be a difference between traumatic and other memory. It is questionable, however, whether responses provoked by reading a script to subjects would permit conclusions about “memory” in the usual sense.

Furthermore, the authors reported that the 11 subjects with PTSD collectively had nine comorbid axis I diagnoses and that five had current nicotine abuse, while their comparison subjects had no such conditions. The authors' failure to control for this factor in their analysis suggests strongly that their conclusions are not legitimate with respect to memory. The predominance of differences in frontal and limbic regions makes it seem far more likely that their results reflect differences in emotional arousal, which is not surprising given the axis I characteristics of their PTSD subjects. Such responses hardly constitute proof of a difference in memory.

Reference

1. Lanius RA, Williamson PC, Densmore M, Boksman K, Neufeld RW, Gati JS, Menon RS: The nature of traumatic memories: a 4-T fMRI functional connectivity analysis. *Am J Psychiatry* 2004; 161:36–44

HARRISON G. POPE, JR., M.D.
Boston, Mass.

Dr. Lanius Replies

TO THE EDITOR: I thank Dr. Pope for addressing the issues of the script-driven imagery symptom provocation paradigm as a means of examining memory recall and the influence of comorbid conditions on the results of our functional connectivity study with PTSD patients.

The script-driven imagery symptom provocation paradigm has been a standard and well-established symptom provoca-